tiprankstipranks
Ocuphire Pharma (OCUP)
NASDAQ:OCUP

Ocuphire Pharma Stock Analysis & Ratings

OCUP Stock Chart & Stats

Day’s Range$1.94 - $2.1608
52-Week Range$1.80 - $7.00
Previous Close$1.99
Volume65.81K
Average Volume (3M)192.68K
Market Cap$41.36M
P/E Ratio-0.5
Beta0.32
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-4.70


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

OCUP FAQ

What was Ocuphire Pharma’s price range in the past 12 months?
Ocuphire Pharma lowest stock price was $1.80 and its highest was $7.00 in the past 12 months.
    What is Ocuphire Pharma’s market cap?
    Ocuphire Pharma’s market cap is $41.36M.
      What is Ocuphire Pharma’s price target?
      The average price target for Ocuphire Pharma is $26.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $26.00 ,the lowest forecast is $26.00. The average price target represents 1109.30% Increase from the current price of $2.15.
        What do analysts say about Ocuphire Pharma?
        Ocuphire Pharma’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Ocuphire Pharma’s upcoming earnings report date?
          Ocuphire Pharma’s upcoming earnings report date is Aug 11, 2022 which is in 87 days.
            How were Ocuphire Pharma’s earnings last quarter?
            Ocuphire Pharma released its earnings results on May 06, 2022. The company reported -$0.35 earnings per share for the quarter, the consensus estimate of -$0.35 by $0.
              Is Ocuphire Pharma overvalued?
              According to Wall Street analysts Ocuphire Pharma’s price is currently Undervalued.
                Does Ocuphire Pharma pay dividends?
                Ocuphire Pharma does not currently pay dividends.
                What is Ocuphire Pharma’s EPS estimate?
                Ocuphire Pharma’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Ocuphire Pharma have?
                Ocuphire Pharma has 19,240,000 shares outstanding.
                  What happened to Ocuphire Pharma’s price movement after its last earnings report?
                  Ocuphire Pharma reported an EPS of -$0.35 in its last earnings report, expectations of -$0.35. Following the earnings report the stock price went down -1.794%.
                    Which hedge fund is a major shareholder of Ocuphire Pharma?
                    Currently, no hedge funds are holding shares in OCUP

                    ---

                    Ocuphire Pharma Stock Analysis

                    The Ocuphire Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Ocuphire Pharma

                    Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

                    ---
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Cyclacel Pharmaceuticals
                    Bristol Myers
                    Exelixis
                    Merck & Company
                    Celldex

                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis